Home > Publications Database > Dementia and COVID-19: A Case Report and Literature Review on Pain Management. > print

001     163496
005     20230915090523.0
024 7 _ |a 10.3390/ph15020199
|2 doi
024 7 _ |a pmid:35215311
|2 pmid
024 7 _ |a pmc:PMC8879883
|2 pmc
037 _ _ |a DZNE-2022-00256
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Scuteri, Damiana
|0 0000-0001-5846-7058
|b 0
245 _ _ |a Dementia and COVID-19: A Case Report and Literature Review on Pain Management.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1654870024_23355
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The coronavirus disease 2019 (COVID-19) pandemic imposes an unprecedented lifestyle, dominated by social isolation. In this frame, the population to pay the highest price is represented by demented patients. This group faces the highest risk of mortality, in case of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection, and they experience rapid cognitive deterioration, due to lockdown measures that prevent their disease monitoring. This complex landscape mirrors an enhancement of neuropsychiatric symptoms (NPSs), with agitation, delirium and reduced motor performances, particularly in non-communicative patients. Due to the consistent link between agitation and pain in these patients, the use of antipsychotics, increasing the risk of death during COVID-19, can be avoided or reduced through an adequate pain treatment. The most suitable pain assessment scale, also feasible for e-health implementation, is the Mobilization-Observation-Behaviour-Intensity-Dementia (MOBID-2) pain scale, currently under validation in the Italian real-world context. Here, we report the case of an 85-year-old woman suffering from mild cognitive impairment, subjected to off-label treatment with atypical antipsychotics, in the context of undertreated pain, who died during the pandemic from an extensive brain hemorrhage. This underscores the need for appropriate assessment and treatment of pain in demented patients.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a COVID-19
|2 Other
650 _ 7 |a MOBID-2
|2 Other
650 _ 7 |a NPSs
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a pain assessment
|2 Other
650 _ 7 |a tele-neurorehabilitation
|2 Other
700 1 _ |a Contrada, Marianna
|0 0000-0002-9825-1347
|b 1
700 1 _ |a Tonin, Paolo
|0 0000-0002-4867-1378
|b 2
700 1 _ |a Corasaniti, Maria Tiziana
|0 0000-0001-6472-0697
|b 3
700 1 _ |a Nicotera, Pierluigi
|0 P:(DE-2719)2010732
|b 4
|u dzne
700 1 _ |a Bagetta, Giacinto
|0 0000-0001-8540-6218
|b 5
773 _ _ |a 10.3390/ph15020199
|g Vol. 15, no. 2, p. 199 -
|0 PERI:(DE-600)2193542-7
|n 2
|p 199
|t Pharmaceuticals
|v 15
|y 2022
|x 1424-8247
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/163496/files/DZNE-2022-00256.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/163496/files/DZNE-2022-00256.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:163496
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2010732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-06-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-06-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-06-15
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-06-15
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-06-15
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-15T12:16:46Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1030000
|k Scientific board
|l Scientific board
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013003
980 _ _ |a I:(DE-2719)1030000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21